Adjuvant TKI therapy in resected -mutant non-small-cell lung cancer-ready for prime time?
作者信息
Arulananda Surein, John Thomas
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Australia.
出版信息
Transl Lung Cancer Res. 2020 Oct;9(5):1728-1731. doi: 10.21037/tlcr-20-615.
Abstract
摘要
相似文献
1
Adjuvant TKI therapy in resected -mutant non-small-cell lung cancer-ready for prime time?
Transl Lung Cancer Res. 2020 Oct;9(5):1728-1731. doi: 10.21037/tlcr-20-615.
2
Mutation Profile of Resected -Mutated Lung Adenocarcinoma by Next-Generation Sequencing.
Oncologist. 2019 Oct;24(10):1368-1374. doi: 10.1634/theoncologist.2018-0567. Epub 2019 Mar 14.
3
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
Transl Lung Cancer Res. 2015 Feb;4(1):82-93. doi: 10.3978/j.issn.2218-6751.2014.11.08.
4
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Lung Cancer. 2019 Nov;137:7-13. doi: 10.1016/j.lungcan.2019.08.002. Epub 2019 Aug 5.
5
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Lung Cancer. 2019 Oct;136:6-14. doi: 10.1016/j.lungcan.2019.08.001. Epub 2019 Aug 2.
6
Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer.
Med Oncol. 2015 Dec;32(12):256. doi: 10.1007/s12032-015-0704-x. Epub 2015 Oct 23.
7
Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):604-613. doi: 10.1016/j.ijrobp.2019.02.051. Epub 2019 Mar 6.
8
Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Clin Lung Cancer. 2018 Nov;19(6):484-492. doi: 10.1016/j.cllc.2018.05.007. Epub 2018 May 26.
9
Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
Eur J Cardiothorac Surg. 2015 Mar;47(3):550-5. doi: 10.1093/ejcts/ezu227. Epub 2014 Jun 3.
10
A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Clin Lung Cancer. 2015 Nov;16(6):e173-81. doi: 10.1016/j.cllc.2015.04.002. Epub 2015 Apr 20.
本文引用的文献
1
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
2
RET-rearranged non-small-cell lung cancer and therapeutic implications.
Intern Med J. 2019 Dec;49(12):1541-1545. doi: 10.1111/imj.14654.
3
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
4
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
J Clin Oncol. 2020 Jan 10;38(2):115-123. doi: 10.1200/JCO.19.01488. Epub 2019 Nov 4.
5
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in -Mutated Lung Cancer.
J Clin Oncol. 2020 Jan 10;38(2):124-136. doi: 10.1200/JCO.19.01154. Epub 2019 Aug 14.
6
Standard dose osimertinib for erlotinib refractory T790M-negative -mutant non-small cell lung cancer with leptomeningeal disease.
J Thorac Dis. 2019 May;11(5):1756-1764. doi: 10.21037/jtd.2019.05.41.
7
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
8
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Mol Cancer. 2018 Feb 19;17(1):38. doi: 10.1186/s12943-018-0777-1.
9
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
10
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
J Thorac Oncol. 2017 Nov;12(11):1728-1732. doi: 10.1016/j.jtho.2017.08.006. Epub 2017 Aug 24.
Zotero 插件